Investors in RGNX Invited to Take Charge in REGENXBIO Securities Fraud Lawsuit

RGNX investors may have a unique opportunity to take the lead in a securities fraud lawsuit against REGENXBIO, Inc. This legal action stems from allegations of misleading statements made by the company that have potentially harmed investors. The Rosen Law Firm, P.A. is actively pursuing this case, representing investors who have suffered financial losses as a result of these alleged fraudulent activities.

The lawsuit centers on claims that REGENXBIO, Inc. failed to disclose crucial information to investors regarding the efficacy of its lead product candidate, RGX-314, which was aimed at treating wet age-related macular degeneration (AMD). The company allegedly made false and misleading statements regarding the results of its Phase II trial for RGX-314, exaggerating the drug’s success and downplaying negative outcomes. As a result, investors may have been misled into believing that the drug was more promising than it actually was, leading to financial losses when the truth emerged.

Investors who purchased REGENXBIO, Inc. securities between February 26, 2020, and February 18, 2021, and suffered losses are encouraged to join the lawsuit. By participating, investors can seek to recover damages for their financial losses resulting from the alleged securities fraud committed by the company. The Rosen Law Firm, P.A. is dedicated to holding REGENXBIO, Inc. accountable for its actions and seeking justice for investors who have been impacted by this alleged wrongdoing.

Investors who choose to participate in the lawsuit will have the opportunity to take an active role in seeking justice and holding the company accountable for its alleged misconduct. The legal process can help investors recover financial losses and send a message that securities fraud will not be tolerated. By joining together in this legal action, investors can assert their rights and seek to obtain compensation for the harm they have suffered as a result of the alleged fraudulent activities of REGENXBIO, Inc.

The Rosen Law Firm, P.A. has a strong track record of representing investors in securities fraud cases and is committed to fighting for the rights of those who have been harmed by corporate misconduct. The firm provides experienced legal representation and works tirelessly to pursue justice on behalf of its clients. Through this lawsuit, investors have the opportunity to stand up against alleged securities fraud and seek redress for the losses they have incurred.

In conclusion, investors who have suffered financial losses due to the alleged securities fraud committed by REGENXBIO, Inc. have the opportunity to participate in a lawsuit led by The Rosen Law Firm, P.A. By joining this legal action, investors can seek to recover damages for the harm they have experienced as a result of the company’s misleading statements and alleged misconduct. This lawsuit provides a platform for investors to seek justice and hold REGENXBIO, Inc. accountable for its actions.